athira pharma inc - ATHA
ATHA
Close Chg Chg %
3.95 -0.08 -2.03%
Closed Market
3.87
-0.08 (2.03%)
Volume: 17.97K
Last Updated:
Dec 12, 2025, 4:00 PM EDT
Company Overview: athira pharma inc - ATHA
ATHA Key Data
| Open $3.89 | Day Range 3.86 - 4.07 |
| 52 Week Range 2.20 - 6.09 | Market Cap $15.62M |
| Shares Outstanding 3.94M | Public Float 3.75M |
| Beta 2.96 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$9.66 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 19.12K |
ATHA Performance
| 1 Week | -2.03% | ||
| 1 Month | -14.38% | ||
| 3 Months | 7.50% | ||
| 1 Year | -33.83% | ||
| 5 Years | -98.75% |
ATHA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About athira pharma inc - ATHA
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
ATHA At a Glance
Athira Pharma, Inc.
18706 North Creek Parkway
Bothell, Washington 98011
| Phone | 1-425-620-8501 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -96,940,000.00 | |
| Sector | Health Technology | Employees | 26 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ATHA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.511 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.287 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.044 |
ATHA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,728,461.538 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ATHA Liquidity
| Current Ratio | 4.175 |
| Quick Ratio | 4.175 |
| Cash Ratio | 3.904 |
ATHA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -88.52 |
| Return on Equity | -110.77 |
| Return on Total Capital | -210.474 |
| Return on Invested Capital | -109.506 |
ATHA Capital Structure
| Total Debt to Total Equity | 2.714 |
| Total Debt to Total Capital | 2.642 |
| Total Debt to Total Assets | 2.07 |
| Long-Term Debt to Equity | 1.791 |
| Long-Term Debt to Total Capital | 1.743 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Athira Pharma Inc - ATHA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 479.00K | 1.05M | 969.00K | 970.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 479.00K | 1.05M | 969.00K | 970.00K | |
Depreciation
| 479.00K | 1.05M | 969.00K | 970.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -76.05% | +118.79% | -7.54% | +0.10% | |
Gross Income
| (479.00K) | (1.05M) | (969.00K) | (970.00K) | |
Gross Income Growth
| +76.05% | -118.79% | +7.54% | -0.10% | |
Gross Profit Margin
| - | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 63.54M | 92.97M | 126.13M | 95.81M | |
Research & Development
| 42.31M | 60.62M | 92.82M | 69.71M | |
Other SG&A
| 21.23M | 32.35M | 33.30M | 26.09M | |
SGA Growth
| +253.11% | +46.31% | +35.66% | -24.04% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 10.00M | (1.63M) | 4.13M | |
EBIT after Unusual Expense
| (64.02M) | (104.02M) | (125.47M) | (100.90M) | |
Non Operating Income/Expense
| 9.17M | 8.38M | 7.79M | 3.96M | |
Non-Operating Interest Income
| 337.00K | 3.22M | 7.64M | 3.96M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 3.00K | - |
Interest Expense Growth
| - | - | -99.18% | -100.00% | - |
Gross Interest Expense
| - | - | - | 3.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (54.85M) | (95.64M) | (117.67M) | (96.94M) | |
Pretax Income Growth
| -174.88% | -74.36% | -23.04% | +17.62% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (54.85M) | (95.64M) | (117.67M) | (96.94M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (54.85M) | (95.64M) | (117.67M) | (96.94M) | |
Net Income Growth
| -174.88% | -74.36% | -23.04% | +17.62% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (54.85M) | (95.64M) | (117.67M) | (96.94M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (54.85M) | (95.64M) | (117.67M) | (96.94M) | |
EPS (Basic)
| -14.8568 | -25.3461 | -30.9499 | -25.1917 | |
EPS (Basic) Growth
| -141.86% | -70.60% | -22.11% | +18.60% | |
Basic Shares Outstanding
| 3.69M | 3.77M | 3.80M | 3.85M | |
EPS (Diluted)
| -14.8568 | -25.3461 | -30.9499 | -25.1917 | |
EPS (Diluted) Growth
| -141.86% | -70.60% | -22.11% | +18.60% | |
Diluted Shares Outstanding
| 3.69M | 3.77M | 3.80M | 3.85M | |
EBITDA
| (63.54M) | (92.97M) | (126.13M) | (95.81M) | |
EBITDA Growth
| -253.11% | -46.31% | -35.66% | +24.04% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 4.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.58 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -6.24 | |
| Last Quarter’s Earnings | -1.68 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -25.20 | Next Fiscal Year Estimate | -4.87 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | N/A | 1 | 1 |
| Mean Estimate | -0.58 | N/A | -6.24 | -4.87 |
| High Estimates | -0.58 | N/A | -6.24 | -4.87 |
| Low Estimate | -0.58 | N/A | -6.24 | -4.87 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 0 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Athira Pharma Inc - ATHA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Athira Pharma Inc - ATHA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 6, 2025 | Javier San Martin CHIEF MEDICAL OFFICER | 93,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Robert Renninger VP of Finance | 24,718 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Robert Renninger VP of Finance | 89,724 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.56 per share | 50,245.44 |
| Jan 6, 2025 | Robert Renninger VP of Finance | 92,605 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Robert Renninger VP of Finance | 80,246 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.55 per share | 44,135.30 |
| Jan 6, 2025 | Kevin Church CHIEF SCIENTIFIC OFFICER | 73,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Kevin Church CHIEF SCIENTIFIC OFFICER | 130,761 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.56 per share | 73,226.16 |
| Jan 6, 2025 | Kevin Church CHIEF SCIENTIFIC OFFICER | 139,271 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Kevin Church CHIEF SCIENTIFIC OFFICER | 102,604 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.55 per share | 56,432.20 |
| Jan 6, 2025 | Mark J. Litton President and CEO; Director | 267,698 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Javier San Martin CHIEF MEDICAL OFFICER | 35,841 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.56 per share | 20,070.96 |
| Jan 6, 2025 | Javier San Martin CHIEF MEDICAL OFFICER | 46,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Mark F. Worthington General Counsel and CCO | 73,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Mark F. Worthington General Counsel and CCO | 83,735 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.56 per share | 46,891.60 |
| Jan 6, 2025 | Mark F. Worthington General Counsel and CCO | 92,245 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Mark F. Worthington General Counsel and CCO | 55,578 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.55 per share | 30,567.90 |
| Jan 6, 2025 | Mark J. Litton President and CEO; Director | 216,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Mark J. Litton President and CEO; Director | 242,591 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.56 per share | 135,850.96 |